Astellas's Vesicare to be launched soon

Astellas Pharma Korea said on October 29 that Vesicare (solifenacin succinate) for the treatment of the overactive bladder (OAB) with the indication of urinary frequency, urgency and urge incontinence associated with OAB will be launched in Korea, following its insurance price listing with the integrated price of 1,061 won for 5 mg and 10 mg tablets, according to a company executive.

However...